Company profile
Mallinckrodt
Specialty pharma -- reorganizing post-Chapter-11 (targeting a 2026 NYSE relisting as "Keenova"), ticker deliberately left null given the transitional OTC listing
Privately held: no public share price · Ireland
Assets
(4 total)
4Total Assets
4Approved
0Phase 3 / Filed
0Phase 1–2 / Early
6Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | —Small molecule | Migraine | |
nitric oxide(INOmax) | Approved | Nitric oxideOther | Hypertension |
| Approved | Melanocortin receptors (primarily MC2R on the adrenal cortex) · Melanocortin 2 receptor (MC2R) (agonist)Peptide | Systemic Lupus ErythematosusRheumatoid ArthritisMultiple SclerosisEpilepsy Multiple Sclerosis Exacerbations | |
| Approved | —Small molecule | Migraine |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.